Study Finds Lower Pregnancy Risks In HPV-Vaccinated Women
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A Swedish national case-control study found that women vaccinated against HPV before pregnancy had modestly lower odds of preterm, very preterm and spontaneous preterm birth than unvaccinated women. The associations were stronger for some outcomes among those vaccinated before age 17, but the observational study cannot establish that vaccination caused the differences.

A Swedish national case-control study covering 624,713 singleton births found that women vaccinated against human papillomavirus (HPV) before pregnancy had modestly lower odds of several preterm birth outcomes than unvaccinated women. The findings, published in The BMJ, describe associations and do not show that HPV vaccination itself caused the differences.

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The researchers examined births to first-time mothers aged 16 to 35 in Swedish national registers between 2006 and 2023. Among eligible births, 14.8% of women had received a quadrivalent HPV vaccine before pregnancy. The analysis excluded women whose first HPV vaccine was a bivalent or nine-valent vaccine, and matched each pregnancy-outcome case with as many as 10 controls without that outcome.

Compared with unvaccinated women, vaccinated women had lower adjusted odds of preterm birth (adjusted odds ratio 0.95), very preterm birth (0.85) and spontaneous preterm birth (0.95). The researchers also reported lower odds of preterm prelabor rupture of membranes (0.93) and a severely small-for-gestational-age infant (0.92). No significant differences were found for membrane rupture overall, stillbirth or neonatal mortality.

For women vaccinated before age 17, the reported odds were lower for preterm birth (0.90) and spontaneous preterm birth (0.89) than for unvaccinated women. This age group also had lower odds of preterm prelabor rupture of membranes and severe small-for-gestational-age birth. The study reported lower odds of severe small-for-gestational-age birth among women vaccinated at 17 or older, and lower odds of stillbirth in that group; these are associations, not proof of protection.

At a glance
reportWhen: Study published October 12, 2026; analy…
The developmentA Swedish study of nearly 625,000 births reports lower odds of several preterm birth outcomes among women who received quadrivalent HPV vaccination before pregnancy.

Potential Benefits Beyond Cancer Prevention

The results may matter to public-health planning because they raise the possibility that HPV vaccination is associated with pregnancy outcomes as well as cancer prevention. The researchers said even modest differences could have implications across a large population, while emphasizing that the individual-level differences were relatively small. Their findings could prompt further research and inform future assessments of vaccination programs, but they do not establish that vaccination prevents pregnancy complications.

The study authors, Jiayao Lei and Zhongsong Zhang of Karolinska Institute, told MedPage Today that policy and cost-effectiveness analyses could account for both cancer prevention and possible reductions in pregnancy-related complications. Such analyses would need to treat the pregnancy findings cautiously until the association is better tested and its cause is clearer.

Products Worth Considering

Therabody SmartGoggles 2nd Generation Heated Eye and Temple Massager

Therabody SmartGoggles 2nd Generation Heated Eye and Temple Massager

As an affiliate, we earn on qualifying purchases.

How the Swedish Study Was Designed

The study used nationwide registers to compare pregnancy outcomes among vaccinated and unvaccinated women, focusing on quadrivalent HPV vaccination received before pregnancy. Its case-control design and matching were intended to help account for differences between groups, but cannot remove every possible source of bias. The analysis focused on first-time mothers and singleton births, so its results do not automatically apply to every pregnancy or population.

The findings also sit alongside established HPV vaccination programs aimed at preventing HPV infections and related cancers. In the United States, the American Academy of Pediatrics recommends a two-dose series of the nine-valent vaccine beginning between ages 9 and 12. The Swedish study assessed a different vaccine type and does not, by itself, change vaccination recommendations.

“Our findings highlight the importance of timely HPV vaccination and suggest that its potential benefits may extend beyond cancer prevention to reproductive health.”

— Jiayao Lei and Zhongsong Zhang, Karolinska Institute researchers, speaking to MedPage Today

Cause and Mechanism Remain Unclear

Because this was an observational study, it cannot establish that HPV vaccination caused lower odds of the reported outcomes. The researchers said residual confounding may remain, including differences related to catch-up or opportunistic vaccination, prior HPV exposure, and sexual or reproductive behavior, particularly among women vaccinated at age 17 or older. They also could not fully assess differences in preventive interventions for preterm birth.

The study found that associations with preterm birth-related outcomes weakened after the researchers adjusted for high-grade cervical lesions diagnosed before childbirth. Such lesions were recorded in 0.6% of vaccinated women and 3.7% of unvaccinated women. This pattern may be consistent with a role for preventing lesions and subsequent cervical treatment, but the researchers lacked detailed treatment data and said the analysis was exploratory. The biological explanation is therefore not settled.

Further Studies Must Test the Link

The report does not announce a change to vaccination guidance or establish a new clinical recommendation. The next step is further research to determine whether the associations hold in other populations and whether they can be explained by vaccination, prevention of cervical lesions and treatment, or other differences between groups. More detailed information on cervical procedures and pregnancy-related care could help clarify the possible pathways.

Until evidence from additional studies is available, the findings should be read as a population-level association rather than a promise of lower pregnancy risk for an individual. Decisions about vaccination and pregnancy care should follow guidance from qualified health professionals and public-health authorities.

Key Questions

What did the Swedish study find?

Women vaccinated against HPV before pregnancy had lower adjusted odds of preterm, very preterm and spontaneous preterm birth than unvaccinated women. The study also reported associations with some other outcomes, but not with membrane rupture overall, stillbirth or neonatal mortality across the vaccinated group.

Does the study prove HPV vaccination prevents preterm birth?

No. It was an observational case-control study, so it can identify an association but cannot establish that vaccination caused the difference. Other differences between vaccinated and unvaccinated women may have affected the results.

Were the associations stronger for women vaccinated before age 17?

For preterm birth and spontaneous preterm birth, the reported associations were stronger among women vaccinated before age 17. That finding does not prove that age at vaccination caused the difference.

Did the study change HPV vaccine recommendations?

The report describes study findings and does not announce a change to vaccination guidance. In the United States, the American Academy of Pediatrics recommends a two-dose series of the nine-valent HPV vaccine beginning between ages 9 and 12; individuals should consult qualified health professionals about personal medical decisions.

Source: rss

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

When Drinking Stopped Being Fun And Why I Quit

A Tiny Buddha writer says anxiety, blackouts and concerns about parenting led her to stop drinking; she reports reaching 10 months sober.

Oxford Population Health Surges In Global Coverage

Oxford Population Health’s research coverage has surged globally, with media mentions increasing over fourfold, signaling rising interest in its work.

He Changed The World Of Organ Transplants. Would He Die Waiting For His Own?

A story titled ‘He Changed the World of Organ Transplants. Would He Die Waiting for His Own?’ is drawing reader and search interest. Details of the case remain unconfirmed.

Health Catalyst Surges In Global Coverage

Health Catalyst experiences a surge in international coverage, with 34 mentions in recent media analysis, highlighting its rising prominence.